Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to -$40.4 million.

  • Capricor Therapeutics' Income towards Parent Company fell 95.68% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.4 million, marking a year-over-year decrease of 100.10%. This contributed to the annual value of -$40.4 million for FY2024, which is 80.60% down from last year.
  • As of FY2024, Capricor Therapeutics' Income towards Parent Company stood at -$40.4 million, which was down 80.60% from -$22.3 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Income towards Parent Company registered a high of -$13.7 million during FY2020, and its lowest value of -$40.4 million during FY2024.
  • Its 3-year average for Income towards Parent Company is -$30.6 million, with a median of -$29.2 million in 2022.
  • In the last 5 years, Capricor Therapeutics' Income towards Parent Company climbed by 23.40% in 2023 and then crashed by 80.60% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Income towards Parent Company (Yearly) stood at -$13.7 million in 2020, then plummeted by 52.90% to -$20.9 million in 2021, then tumbled by 39.72% to -$29.2 million in 2022, then grew by 23.40% to -$22.3 million in 2023, then slumped by 80.60% to -$40.4 million in 2024.